SEC Comment Letter for GT Biopharma, Inc. (GTBP) (CIK 0000109657) (GTBP) — Jan 19, 2011

GT Biopharma, Inc. (GTBP) (CIK 0000109657)
Date: Jan. 19, 2011 · CIK: 0000109657 · Accession: 0000000000-11-003730

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 000-08092

Date

January 19, 2011

Author

Jeffrey P. Riedler

Form

UPLOAD

Company

GT Biopharma, Inc. (GTBP) (CIK 0000109657)

Letter

January 19, 2011 Anthony J. Cataldo Chief Executive Officer Oxis International, Inc. 468 N. Camden Dr., 2nd Floor Beverly Hills, CA 90210 Re: Oxis International, Inc. Form 10-K for the Fiscal Year Ended December 31, 2009 Filed March 30, 2010 File No. 000-08092

Dear Mr. Cataldo: We have completed our review of your fili ngs and do not have any further comments at this time. Sincerely,

Jeffrey P. Riedler Assistant Director

cc: Istvan Benko (TroyGould PC)

Show Raw Text

January 19, 2011
 Anthony J. Cataldo Chief Executive Officer  Oxis International, Inc. 468 N. Camden Dr., 2nd Floor Beverly Hills, CA 90210
 Re: Oxis International, Inc.
 Form 10-K for the Fiscal Year Ended December 31, 2009
  Filed March 30, 2010
  File No. 000-08092

 Dear Mr. Cataldo:   We have completed our review of your fili ngs and do not have any further comments at
this time.
Sincerely,

Jeffrey P. Riedler Assistant Director

cc: Istvan Benko (TroyGould PC)

SecProbe.io